


This listing of claims will replace all prior versions, and listings, of claims in the application:


**Listing of Claims:**

---

Claim 1 (currently amended): A method of ~~treating~~ preventing cataracts, retinopathy, lens cell damage and retinal cell damage caused by diabetes ~~a diabetic complication in the eye~~ comprising administering to a patient an effective amount of one or more compounds of the formula:



or



wherein:

T is independently CR, NR, N, S or O;


X is independently O, NR, N or S;

Y is independently O, NR, N or S;

Z is independently C, N, S or O;

a is 0 or 1;

R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are, independently, R,



wherein R is independently H, OH, alkyl, alkenyl or alkynyl, an aromatic ring system, amino, sulfhydryl, or sulfonyl, M is a divalent alkyl, alkenyl or alkynyl, aromatic ring system, or sulfonyl, W is Cl, F, Br or OCl, and A is an aromatic ring system;

R<sup>2</sup>, R<sup>8</sup> and R<sup>9</sup> are independently R as defined above; and


R<sup>6</sup> is independently R, NH<sub>2</sub>, OH, or OCOR where R is as set forth above;

R<sup>7</sup> is independently OH or H; or

R<sup>6</sup> and R<sup>7</sup> taken together are O;

and pharmaceutically acceptable salts or esters of the foregoing, as well as optical isomers thereof.


Claim 2 (original): The method of claim 1, wherein said patient is a dog and said compound is:



Claim 3 (original): The method of claim 2, wherein the compound is administered orally.

Claim 4 (original): The method of claim 2, wherein the compound is administered topically.

Claim 5 (original): The method of claim 1, wherein said patient is a human and said compound is:




Claim 6 (original): The method of claim 5, wherein the compound is administered orally.


Claim 7 (original): The method of claim 5, wherein the compound is administered topically.

Claim 8 (withdrawn): A method of inhibiting aldose reductase activity in cells, comprising

contacting the cells with an effective amount of a compound of formula:



or



wherein:

T is independently CR, NR, N, S or O;


X is independently O, NR, N or S;

Y is independently O, NR, N or S;

Z is independently C, N, S or O;

a is 0 or 1,

R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are, independently, R,



wherein R is independently H, OH, alkyl, alkenyl or alkynyl, an aromatic ring system, amino, sulfhydryl, or sulfonyl, M is a divalent alkyl, alkenyl or alkynyl, aromatic ring system, or sulfonyl, W is Cl, F, Br or OCl, and A is an aromatic ring system;

$\text{R}^2$ ,  $\text{R}^8$  and  $\text{R}^9$  are independently R as defined above; and


$\text{R}^6$  is independently R,  $\text{NH}_2$ , OH, or OCOR where R is as set forth above;

$\text{R}^7$  is independently OH or H; or

$\text{R}^6$  and  $\text{R}^7$  taken together are O;

and pharmaceutically acceptable salts or esters of the foregoing, as well as optical isomers thereof.


Claim 9 (withdrawn): The method of claim 8, wherein said patient is a dog and said compound is:



Claim 10 (withdrawn): The method of claim 9, wherein the compound is administered orally.

Claim 11 (withdrawn): The method of claim 9, wherein the compound is administered topically.


Claim 12 (withdrawn): The method of claim 8, wherein said patient is a human and said compound is:




Claim 13 (withdrawn): The method of claim 12, wherein the compound is administered orally.

Claim 14 (withdrawn): The method of claim 12, wherein the compound is administered topically.

Claim 15 (withdrawn): A method of treating retinopathy comprising:  
administering to a patient an effective amount of a compound of formula:



or



wherein:

T is independently CR, NR, N, S or O;


X is independently O, NR, N or S;

Y is independently O, NR, N or S;

Z is independently C, N, S or O;

a is 0 or 1,

R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are, independently, R,



wherein R is independently H, OH, alkyl, alkenyl or alkynyl, an aromatic ring system, amino, sulfhydryl, or sulfonyl, M is a divalent alkyl, alkenyl or alkynyl, aromatic ring system, or sulfonyl, W is Cl, F, Br or OCl, and A is an aromatic ring system;

R<sup>2</sup>, R<sup>8</sup> and R<sup>9</sup> are independently R as defined above; and

R<sup>6</sup> is independently R, NH<sub>2</sub>, OH, or OCOR where R is as set forth above;

R<sup>7</sup> is independently OH or H; or

R<sup>6</sup> and R<sup>7</sup> taken together are O;


and pharmaceutically acceptable salts or esters of the foregoing, as well as optical isomers thereof.

Claim 16 (withdrawn): The method of claim 15, wherein the compound is administered orally.

Claim 17 (withdrawn): The method of claim 15, wherein the compound is administered topically.




Claim 18 (withdrawn): The method of claim 15, wherein said patient is a dog, and said compound is



Claim 19 (withdrawn): A method of decreasing the loss of PKC in diabetic patients comprising administering to a patient an effective amount of one or more compounds of claim 1.


Claim 20 (withdrawn): A method of inhibiting polyol accumulation in diabetic patients comprising administering to a patient an effective amount of one or more compounds of claim 1.

Claim 21 (withdrawn): A pharmaceutical composition comprising a compound with formula:




wherein the compound is useful to treat a disorder associated with the activity of aldose reductase.

Claim 22 (withdrawn): A method of preparing a pharmaceutical composition comprising:  
bringing a compound of formula:



or



wherein:

T is independently CR, NR, N, S or O;


X is independently O, NR, N or S;

Y is independently O, NR, N or S;

Z is independently C, N, S or O;

a is 0 or 1,

R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are, independently, R,



wherein R is independently H, OH, alkyl, alkenyl or alkynyl, an aromatic ring system, amino, sulfhydryl, or sulfonyl, M is a divalent alkyl, alkenyl or alkynyl, aromatic ring system, or sulfonyl, W is Cl, F, Br or OCl, and A is an aromatic ring system;

$\text{R}^2$ ,  $\text{R}^8$  and  $\text{R}^9$  are independently R as defined above; and

$\text{R}^6$  is independently R,  $\text{NH}_2$ , OH, or  $\text{OCOR}$  where R is as set forth above;

$\text{R}^7$  is independently OH or H; or

$\text{R}^6$  and  $\text{R}^7$  taken together are O;

and pharmaceutically acceptable salts or esters of the foregoing, as well as optical isomers thereof, into association with a pharmaceutically acceptable carrier.

T is independently CR, NR, N, S or O:


X is independently O, NR, N or S;

Y is independently O, NR, N or S;

Z is independently C, N, S or O;

a is 0 or 1,

$R^1, R^3, R^4$  and  $R^5$  are, independently,  $R$ ,



wherein R is independently H, OH, alkyl, alkenyl or alkynyl, an aromatic ring system, amino, sulfhydryl, or sulfonyl, M is a divalent alkyl, alkenyl or alkynyl, aromatic ring system, or sulfonyl, W is Cl, F, Br or OCl, and A is an aromatic ring system;

R<sup>2</sup>, R<sup>8</sup> and R<sup>9</sup> are independently R as defined above; and

R<sup>6</sup> is independently R, NH<sub>2</sub>, OH, or OCOR where R is as set forth above;

R<sup>7</sup> is independently OH or H; or

R<sup>6</sup> and R<sup>7</sup> taken together are O;

provided that either:

T is independently CR, provided that R is not H, or NR;

X is independently NR or N, provided that R is not H;


Y is independently NR, provided that R is not H; or

R<sup>1</sup>, R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are, independently,


-CH(OR)-OR; -O-CH(OR)-R; -M-O-CH(OR)-R; -M-C(OR)-C(=O)-R; or -M-C(=O)-C(OR)OR.

Claim 24 (currently amended): A method of treating an ocular diabetic complication ~~symptom or condition~~ selected from the group consisting of: ~~retinopathy~~, loss of PKC in eye lens cells, polyol accumulation in the eye, galactitol formation from galactose in lens cells, vascular leakage in the eye,

and expression of aldose reductase in the retina comprising administering to a patient an effective amount of one or more compounds of the formula:



or



wherein:

T is independently CR, NR, N, S or O;


X is independently O, NR, N or S;

Y is independently O, NR, N or S;

Z is independently C, N, S or O;

a is 0 or 1;

$R^1$ ,  $R^3$ ,  $R^4$  and  $R^5$  are, independently, R,



wherein R is independently H, OH, alkyl, alkenyl or alkynyl, an aromatic ring system, amino, sulfhydryl, or sulfonyl, M is a divalent alkyl, alkenyl or alkynyl, aromatic ring system, or sulfonyl, W is Cl, F, Br or OCl, and A is an aromatic ring system;

$R^2$ ,  $R^8$  and  $R^9$  are independently R as defined above; and

$R^6$  is independently R,  $NH_2$ , OH, or OCOR where R is as set forth above;

$R^7$  is independently OH or H; or

$R^6$  and  $R^7$  taken together are O;

and pharmaceutically acceptable salts or esters of the foregoing, as well as optical isomers thereof.